by | Sep 18, 2024 | Publications
Clin Cancer Res. 2024 Sep 11. doi: 10.1158/1078-0432.CCR-24-1798. Online ahead of print. ABSTRACT PURPOSE: CAR T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events including second primary...
by | Sep 18, 2024 | Publications
Clin Hematol Int. 2024 Jul 29;6(3):38-53. doi: 10.46989/001c.121406. eCollection 2024. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is diagnosed in 6,000 people in the UK yearly. A performance status measure, based on the patients’ reported level of physical...
by | Sep 18, 2024 | Publications
Acta Haematol. 2024 Sep 16:1-17. doi: 10.1159/000540232. Online ahead of print. ABSTRACT INTRODUCTION: High-dose therapy with melphalan followed by autologous stem cell transplant at the upfront setting (upfront ASCT) has significantly improved clinical outcomes of...
by | Sep 9, 2024 | Publications
Oncologist. 2024 Sep 5:oyae219. doi: 10.1093/oncolo/oyae219. Online ahead of print. ABSTRACT BACKGROUND: Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on...
by | Aug 24, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Jul 19:S2152-2650(24)00264-7. doi: 10.1016/j.clml.2024.07.008. Online ahead of print. ABSTRACT BACKGROUND: Immunoparesis, defined as suppression of uninvolved polyclonal immunoglobulins, occurs in up to 80% of patients with newly...
by | Aug 19, 2024 | Publications
EJHaem. 2024 Jun 10;5(4):867-878. doi: 10.1002/jha2.905. eCollection 2024 Aug. ABSTRACT The incidence of multiple myeloma (MM) has surged globally, particularly in Latin American countries, and is attributable to an aging population and increased life expectancy. This...
